Clinical Trial

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Name: Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents — clinical trial record (NCT06963346)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).

Protocol Amendment History 1 change

critical Recruitment resumed after suspension 2026-07-31

Trial Details

NCT Number	NCT06963346
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: AstraZeneca
Conditions	Bladder Cancer
Enrollment	12 participants
Start Date	2025-06-24
Primary Completion	2028-04 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-30